JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2025, 74(4):E2-E7 | DOI: 10.36290/csf.2025.036

Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension

Valentyna Volodymyrivna Chopyak1, Igor Grygorovich Hayduchok2, Yuriy Volodymyrovych Fedorov2, Alona Vasylivna Kovpak2, Bogdana Fedorivna Baida2, Oksana Volodymyrivna Levytska2, Volodymyr Antonovych Doroshko3
1 Národní lékařská univerzita Danylo Halytskyi Lvov, Ukrajina
2 Soukromá vysoká škola "Lviv Medical University", Lvov, Ukrajina
3 Bukovinská státní lékařská univerzita

Introduction: The article presents the findings of a clinical trial investigating the impact of quercetin, as an adjunct to antihypertensive therapy, on endothelial function and daily blood pressure profiles.

The aim of the study. To conduct a comparative analysis of the impact of quercetin on 24-hour blood pressure monitoring parameters and cytokine profiles in patients with hypertension.

Materials and methods: A total of 120 patients with stage II hypertension (66 female and 54 male) were enrolled in the study. Patients were divided into 2 groups: Group I (study) – 58 patients who took quercetin (Corvitin®) in addition to basic therapy; II group (comparison) – 62 patients who underwent only basic antihypertensive therapy (Ramipril/Amlodipine).

The results and disscusions: During the administration of quercetin along with the standard basic therapy with the combination of Ramipril/Amlodipine in patients with stage II hypertension of 2–3 degrees of severity, more pronounced significant in the major indices of 24-hour BPM were observed, an increase in the ratio of subjects with a „dipper“ profile due to a decrease in the number of patients with an insufficient reduction in nocturnal BP, an excessive drop in nocturnal BP or its persistent increase. Quercetin reduced markers of endothelial dysfunction, including sVCAM, sICAM-1, ET-1, IL-1α, IL-6, and TNF-α, more effectively than standard therapy alone. Standard antihypertensive therapy had a minimal effect on IL-1α and ET-1 levels.

Conclusion: The use of quercetin reliably reduces the levels of cytokines, which ensures a reduction in the manifestations of endothelial protection and contributes to better control of all blood pressure indices and normalization of the daily profile of blood pressure.

Keywords: endothelin-1, arterial hypertension, ramipril/amlodipine, quercetin

Accepted: November 21, 2025; Published: December 5, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chopyak VV, Grygorovich Hayduchok I, Volodymyrovych Fedorov Y, Kovpak AV, Baida BF, Levytska OV, Antonovych Doroshko V. Efficacy of quercetin and the role of endothelial protection in the treatment of patients with arterial hypertension. Čes. slov. farm. 2025;74(4):E2-7. doi: 10.36290/csf.2025.036.
Download citation

References

  1. Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the treatment of hypertension, 2018. Eur Heart J. 2018;39(33):3021-104. https://doi.org/10.1093/eurheartj/ehy339 Go to original source... Go to PubMed...
  2. Whelton PK, Carey RM, Aronow WS, et al. Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Hypertension. 2018;71(6):1269-324. Go to original source...
  3. Malyarska NV, Kalinichenko MA. Endothelial dysfunction as a universal predictor of cardiovascular diseases and the possibility of its correction in the practice of a family doctor. Medicina Ukr. 2017;1:36-9. https://doi.org/10.37987/1997-9894.2017.1(207).221931. Go to original source...
  4. (Оцінка ефективності метаболічної терапії при розвитку ендотеліальної адгезивної дисфункції у хворих на артеріальну гіпертензію). Achievements of clinical and experimental medicine. 2021;2:77-82. https://doi.org/10.11603/1811-2471.2021.v.i2.11822. Go to original source...
  5. Zhuravleva LV, Kulikova MV. The use of metabolic therapy in patients with comorbid pathology: realities and prospects. Medicina Ukr. 2018;8:42-4. https://doi.org/10.37987/1997-9894.2018.8(224).199837. Go to original source...
  6. Chen S, et al. Binding of quercetin to human serum albumin: A fluorescence spectroscopic study. J Agric Food Chem. 2018;66(12):3158-3165. doi:10.1021/acs.jafc.7b05599. Go to original source...
  7. Srinivas NR, et al. Clinical pharmacokinetics of amlodipine. Clin Pharmacokinet. 2002;41(14):1199-1219. doi:10.2165/00003088-200241140-00004. Go to original source... Go to PubMed...
  8. Nesen AO, Grunchenko MM, Shkapo VL, et al. Cardiovascular risks and comorbidity are an acute problem of public health deterioration. ScienceRise. 2015;1(3):41-8. https://doi.org/10.15587/2313-8416.2015.36749. Go to original source...
  9. Solomenchuk TM, Protsko VV, Vosukh OV, et al. Effectiveness of cardiometabolic therapy in the treatment of acute coronary syndrome without ST-segment elevation in perimenopausal women. Fam Med. 2019;2:66-75. https://doi.org/10.30841/2307-5112.2.2019.175140 Go to original source...
  10. Shalimova AS. Endothelial dysfunction and its correction in patients with hypertension and type 2 diabetes. Int J Endocrinol. 2014;2:33-9. https://doi.org/10.22141/2224-0721.2.58.2014.76471. Go to original source...
  11. Rindina NG. Metabolic therapy of myocardial dysfunction and correction of vascular endothelial function in patients with rheumatoid arthritis in combination with arterial hypertension (PhD thesis). Ministry of Health of Ukraine, State Institution "Zaporizhzhia Medical Academy of Postgraduate Education of the Ministry of Health of Ukraine"; 2020.
  12. Zhdan VM, Kitura OE, Kitura EM, et al. Arterial hypertension and heart failure in general practice. Fam Med. 2020;1-2:85-8. https://doi.org/10.30841/2307-5112.1-2.2020.204541. Go to original source...




Czech and Slovak Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.